Concord Drugs Limited

BSE: 538965
Concord Drugs Limited - pharma in Na, Telangana, India. FY 2026 financials and compliance.
CIN L24230TG1995PLC020093 Incorporated 24 April 1995 ROC Hyderabad HQ Na, Telangana, India
Active Listed - BSE: 538965 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹78.74 Cr
▲ 74.02% YoY
Computed EBITDA · FY 2026
₹4.55 Cr
▲ 9.76% YoY
Net profit · FY 2026
₹1.06 Cr
▲ 213.8% YoY
Authorised capital
₹15.5 Cr
Registered with MCA
Paid-up capital
₹13.18 Cr
Issued & subscribed
Open charges
₹19.33 Cr
Satisfied ₹7.4 Cr
Company age
31 yrs
Est. 1995
Employees · EPFO
20
Latest available

About Concord Drugs Limited

Data last updated: 14 July 2026

Concord Drugs Limited is a public limited company based in Na, Telangana, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 24 April 1995, the company has been in operation for over 31 years.

Registered with ROC Hyderabad under CIN L24230AP1995PLC020093. Listed on BSE: 538965.

Capital: an authorised share capital of ₹15.5 Cr and a paid-up capital of ₹13.18 Cr. It is led by directors including Nagi Reddy Seelam and Koni Reddy Seelam.

Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Survey No.249 Brahmanapally Village Hayatnagar Mandal R.R.D Ist – 501511, Telangana, India.

As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹78.74 Cr, a growth of 74.02% compared to the previous year. The net worth stands at ₹48.51 Cr (up 42.21% YoY). Total assets are valued at ₹74.89 Cr (up 14.96% YoY).

The company has a workforce of approximately 20 employees as per the latest available data.

The company is associated with 1 brand - Concord Drugs. As per MCA filings, the company has open charges of ₹19.33 Cr and satisfied charges of ₹7.4 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website concorddrugs.in.

Company Details of Concord Drugs Limited
CIN L24230TG1995PLC020093
Registration Number 020093
Incorporation Date 24 April 1995
ROC Hyderabad
Listing Status Listed (BSE: 538965)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Nagi Reddy Seelam Managing Director Koni Reddy Seelam Whole-Time Director Seelam Manojkumarreddy Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    Locked
  • Social Media
  • Registered Address
    Survey No.249 Brahmanapally Village Hayatnagar Mandal R.R.D Ist – 501511, Telangana, India
  • Industry
    Pharma, API Manufacturers
Company report
Concord Drugs Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Concord Drugs Limited report

Financials, compliance, directors, charges, ownership and filings for Concord Drugs Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Concord Drugs Limited

Concord Drugs Limited has one previous CIN (Corporate Identification Number): L24230AP1995PLC020093. The current CIN is L24230TG1995PLC020093, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24230TG1995PLC020093 Current
L24230AP1995PLC020093 Previous

Associated Brands with Concord Drugs Limited

Concord Drugs Limited operates one associated brand: Concord Drugs. These brands represent Concord Drugs Limited's diversified market presence and brand portfolio.

Brand Description Website
Concord Drugs
Manufacturer of pharmaceutical formulations and ready-to-fill pellets concorddrugs.in

Business Activity of Concord Drugs Limited

Concord Drugs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Concord Drugs Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Concord Drugs Limited

Concord Drugs Limited is audited by Pundarikashyam and associates (ICAI peer reviewed, certificate valid till 2017-10-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Pundarikashyam and associates (ICAI peer reviewed, certificate valid till 2017-10-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Concord Drugs Limited

Concord Drugs Limited is currently managed by 6 directors, with 13 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Nagi Reddy Seelam
Also directs: Cortex Laboratories Private Limited
Managing Director 04 Apr 2003 23 Years 4 Months Current
Koni Reddy Seelam
Also directs: Proton Remedies Private Limited
Whole-Time Director 10 Jun 2011 15 Years 2 Months Current
Seelam Manojkumarreddy
Also directs: Cortex Laboratories Private Limited, Proton Remedies Private Limited, Seelam Laboratories Private Limited
Whole-Time Director 13 Aug 2021 5 Years 0 Months Current
Nagavenkatahareeshkumar Solleti Director 13 Feb 2021 5 Years 6 Months Current
Sumeela Kasu Director 01 Jun 2022 4 Years 2 Months Current
Satyam Reddy Gopidi Director 30 Sep 2025 0 Years 10 Months Current
View all directors

Financials of Concord Drugs Limited FY 2026 filings available

Concord Drugs Limited reported revenue of ₹78.74 Cr (up 74.02% YoY) for FY 2026.

Revenue · FY 2026
₹78.74 Cr ▲ 74.02%
Profit · FY 2026
₹1.06 Cr ▲ 213.8%
Computed EBITDA · FY 2026
₹4.55 Cr ▲ 9.76%
Revenue₹ Cr · Consolidated050100FY 2023: ₹52 Cr52.1FY 2023FY 2024: ₹45 Cr · -13.7% YoY44.9-13.7%FY 2024FY 2025: ₹45 Cr · +0.7% YoY45.2+0.7%FY 2025FY 2026: ₹79 Cr · +74% YoY78.7+74%FY 2026
Net Profit₹ Cr · Consolidated00.511.5FY 2023: ₹1 Cr1FY 2023FY 2024: ₹0 Cr · -52.1% YoY0.5-52.1%FY 2024FY 2025: ₹0 Cr · -28.8% YoY0.3-28.8%FY 2025FY 2026: ₹1 Cr · +213.8% YoY1.1+213.8%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year02040Q1'25: ₹12 Cr11.7Q1'25Q2'25: ₹12 Cr12.4Q2'25Q3'25: ₹11 Cr10.8Q3'25Q4'25: ₹10 Cr10.4Q4'25Q1'26: ₹14 Cr · +16.4% YoY13.6+16.4%Q1'26Q2'26: ₹10 Cr · -16.9% YoY10.3-16.9%Q2'26Q3'26: ₹17 Cr · +57.1% YoY17+57.1%Q3'26Q4'26: ₹38 Cr · +264.6% YoY37.9+264.6%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Revenue from Operations ₹78.74 Cr ₹45.24 Cr ₹44.92 Cr ₹52.08 Cr
Other Income ₹3.44 Lakh ₹1.44 Lakh ₹92,900 ₹88,600
Total Income ₹78.77 Cr ₹45.26 Cr ₹44.93 Cr ₹52.09 Cr
Cost of Materials Consumed ₹68.03 Cr ₹35.81 Cr ₹33.66 Cr ₹41.16 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹38.37 Lakh -₹58.05 Lakh -₹40.49 Lakh -₹15.67 Lakh
Employee Benefit Expense ₹4.97 Cr ₹4.63 Cr ₹6.08 Cr ₹4.92 Cr
Finance Costs ₹1.71 Cr ₹2.03 Cr ₹1.87 Cr ₹1.71 Cr
Depreciation & Amortisation ₹1.37 Cr ₹1.43 Cr ₹1.56 Cr ₹1.63 Cr
Other Expenses ₹1.6 Cr ₹1.25 Cr ₹1.55 Cr ₹1.58 Cr
Total Expenses ₹77.3 Cr ₹44.57 Cr ₹44.3 Cr ₹50.84 Cr
Profit Before Exceptional Items & Tax ₹1.47 Cr ₹69.14 Lakh ₹62.9 Lakh ₹1.25 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹1.47 Cr ₹69.14 Lakh ₹62.9 Lakh ₹1.25 Cr
Total Tax Expense ₹41.82 Lakh ₹35.52 Lakh ₹15.66 Lakh ₹26.34 Lakh
Net Profit ₹1.06 Cr ₹33.62 Lakh ₹47.24 Lakh ₹98.55 Lakh
  attributable to Owners ₹1.06 Cr - ₹0 ₹0
  attributable to NCI ₹0 - ₹0 ₹0
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income ₹1.06 Cr ₹33.62 Lakh ₹47.24 Lakh ₹98.55 Lakh
EBITDA (computed) ₹4.55 Cr ₹4.15 Cr ₹4.05 Cr ₹4.58 Cr
Basic EPS ₹0.95 ₹0.34 ₹0.47 ₹1.06
Diluted EPS ₹0.95 ₹0.34 ₹0.47 ₹1.06
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹74.89 Cr ₹65.14 Cr ₹58.81 Cr ₹58.23 Cr
Non-current Assets ₹21.58 Cr ₹24.38 Cr ₹14.19 Cr ₹14.77 Cr
Current Assets ₹53.31 Cr ₹40.76 Cr ₹44.62 Cr ₹43.46 Cr
Property, Plant & Equipment ₹10.94 Cr ₹11.57 Cr ₹11.04 Cr ₹12.28 Cr
Inventories ₹25.52 Cr ₹25.27 Cr ₹22.92 Cr ₹20.06 Cr
Trade Receivables ₹24.38 Cr ₹13.6 Cr ₹19.83 Cr ₹15.81 Cr
Cash & Equivalents ₹27.81 Lakh ₹12.09 Lakh ₹14.54 Lakh ₹7.84 Lakh
Equity (Net Worth) ₹48.51 Cr ₹34.11 Cr ₹33.82 Cr ₹31.7 Cr
Equity Share Capital ₹13.18 Cr ₹10 Cr ₹10 Cr ₹9.32 Cr
Borrowings (Non-current) ₹1.81 Cr ₹1.32 Cr ₹64.55 Lakh ₹1.91 Cr
Borrowings (Current) ₹11.79 Cr ₹15.87 Cr ₹15.95 Cr ₹14.23 Cr
Total Debt (computed) ₹13.6 Cr ₹17.19 Cr ₹16.59 Cr ₹16.14 Cr
Current Liabilities ₹21.07 Cr ₹26.18 Cr ₹21.34 Cr ₹21.61 Cr
Total Liabilities ₹26.37 Cr ₹31.03 Cr ₹24.99 Cr ₹26.53 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Operating Cash Flow -₹6.77 Cr ₹3.72 Cr ₹79.23 Lakh ₹1.66 Cr
Investing Cash Flow -₹1.13 Cr -₹2.32 Cr -₹1.01 Cr -₹2.27 Cr
Financing Cash Flow ₹8.06 Cr -₹1.43 Cr ₹28.34 Lakh ₹62.4 Lakh
Capital Expenditure ₹1.17 Cr ₹2.33 Cr ₹1.02 Cr ₹85.66 Lakh
Free Cash Flow (computed) -₹7.93 Cr ₹1.39 Cr -₹22.56 Lakh ₹80.65 Lakh
Dividends Paid ₹0 ₹0 ₹0 ₹0
Net Change in Cash ₹15.72 Lakh -₹2.46 Lakh ₹6.71 Lakh ₹2.15 Lakh
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹37.89 Cr ₹16.97 Cr ₹10.28 Cr ₹13.61 Cr ₹10.39 Cr ₹10.8 Cr ₹12.36 Cr ₹11.69 Cr
Other Income ₹1.08 Lakh ₹2.12 Lakh ₹24,000 ₹0 ₹48,000 ₹0 ₹95,700 ₹100
Total Income ₹37.9 Cr ₹16.99 Cr ₹10.28 Cr ₹13.61 Cr ₹10.4 Cr ₹10.8 Cr ₹12.37 Cr ₹11.69 Cr
Cost of Materials Consumed ₹35.07 Cr ₹14.38 Cr ₹7.76 Cr ₹10.81 Cr ₹8.65 Cr ₹6.72 Cr ₹11.77 Cr ₹8.67 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹95.28 Lakh ₹77,000 -₹4.51 Lakh ₹60.64 Lakh -₹74.49 Lakh ₹1.42 Cr -₹1.61 Cr ₹35.16 Lakh
Employee Benefit Expense ₹1.75 Cr ₹1.24 Cr ₹1.09 Cr ₹88.6 Lakh ₹1.24 Cr ₹1 Cr ₹93.39 Lakh ₹1.46 Cr
Finance Costs ₹39.57 Lakh ₹33.97 Lakh ₹48.81 Lakh ₹49 Lakh ₹61.1 Lakh ₹49.7 Lakh ₹46.59 Lakh ₹45.28 Lakh
Depreciation & Amortisation ₹35.28 Lakh ₹30.67 Lakh ₹33.94 Lakh ₹36.78 Lakh ₹37.76 Lakh ₹37.04 Lakh ₹34.41 Lakh ₹33.86 Lakh
Other Expenses ₹53.24 Lakh ₹41.65 Lakh ₹36.68 Lakh ₹28.55 Lakh ₹20.54 Lakh ₹25.26 Lakh ₹40.63 Lakh ₹38.11 Lakh
Total Expenses ₹37.15 Cr ₹16.69 Cr ₹10.01 Cr ₹13.45 Cr ₹10.34 Cr ₹10.27 Cr ₹12.3 Cr ₹11.65 Cr
Profit Before Exceptional Items & Tax ₹74.76 Lakh ₹29.62 Lakh ₹27.13 Lakh ₹15.85 Lakh ₹5.8 Lakh ₹52.69 Lakh ₹6.58 Lakh ₹4.08 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹74.76 Lakh ₹29.62 Lakh ₹27.13 Lakh ₹15.85 Lakh ₹5.8 Lakh ₹52.69 Lakh ₹6.58 Lakh ₹4.08 Lakh
Total Tax Expense ₹21.96 Lakh ₹7.92 Lakh ₹7.89 Lakh ₹4.07 Lakh ₹1.9 Lakh ₹30.03 Lakh ₹2.23 Lakh ₹1.35 Lakh
Net Profit ₹52.8 Lakh ₹21.7 Lakh ₹19.24 Lakh ₹11.78 Lakh ₹3.9 Lakh ₹22.67 Lakh ₹4.34 Lakh ₹2.73 Lakh
  attributable to Owners ₹52.8 Lakh ₹21.7 Lakh ₹0 - - ₹0 ₹0 -
  attributable to NCI ₹0 ₹0 ₹0 - - ₹0 ₹0 -
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income ₹52.8 Lakh ₹21.7 Lakh ₹19.24 Lakh ₹11.78 Lakh ₹3.9 Lakh ₹22.67 Lakh ₹4.34 Lakh ₹2.73 Lakh
EBITDA (computed) ₹1.5 Cr ₹94.26 Lakh ₹1.1 Cr ₹1.02 Cr ₹1.05 Cr ₹1.39 Cr ₹87.58 Lakh ₹83.23 Lakh
Basic EPS ₹0.47 ₹0.16 ₹0.31 ₹0.12 ₹0.04 ₹0.23 ₹0.04 ₹0.03
Diluted EPS ₹0.47 ₹0.16 ₹0.31 ₹0.12 ₹0.04 ₹0.23 ₹0.04 ₹0.03
Latest 8 quarters shown.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹75.85 Cr ₹36.93 Cr ₹43.26 Cr ₹51.31 Cr ₹58.96 Cr ₹51.36 Cr ₹51.34 Cr ₹48.08 Cr
Other Income ₹3.44 Lakh ₹1.44 Lakh ₹92,900 ₹88,600 ₹10.08 Lakh ₹9.46 Lakh ₹12.01 Lakh ₹8.59 Lakh
Total Income ₹75.88 Cr ₹36.95 Cr ₹43.27 Cr ₹51.32 Cr ₹59.06 Cr ₹51.45 Cr ₹51.46 Cr ₹48.16 Cr
Cost of Materials Consumed ₹64.5 Cr ₹28.22 Cr ₹33.71 Cr ₹40.36 Cr ₹44.41 Cr ₹40.49 Cr ₹42.06 Cr ₹39.14 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹63.98 Lakh -₹58.05 Lakh -₹40.49 Lakh ₹51.56 Lakh -₹2.31 Cr ₹1.69 Cr ₹51.72 Lakh ₹45.59 Lakh
Employee Benefit Expense ₹4.9 Cr ₹4.39 Cr ₹4.95 Cr ₹4.63 Cr ₹4.89 Cr ₹3.76 Cr ₹3.51 Cr ₹2.53 Cr
Finance Costs ₹1.46 Cr ₹1.72 Cr ₹1.59 Cr ₹1.62 Cr ₹1.68 Cr ₹1.42 Cr ₹1.54 Cr ₹1.59 Cr
Depreciation & Amortisation ₹1.36 Cr ₹1.42 Cr ₹1.54 Cr ₹1.6 Cr ₹1.76 Cr ₹1.37 Cr ₹1.46 Cr ₹1.71 Cr
Other Expenses ₹1.58 Cr ₹1.13 Cr ₹1.33 Cr ₹1.47 Cr ₹6.37 Cr ₹2.2 Cr ₹1.91 Cr ₹2.3 Cr
Total Expenses ₹74.43 Cr ₹36.31 Cr ₹42.71 Cr ₹50.2 Cr ₹56.81 Cr ₹50.92 Cr ₹51 Cr ₹47.72 Cr
Profit Before Exceptional Items & Tax ₹1.45 Cr ₹64.13 Lakh ₹55.84 Lakh ₹1.13 Cr ₹2.25 Cr ₹52.88 Lakh ₹45.65 Lakh ₹43.97 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹3.76 Cr ₹0 ₹0
Profit Before Tax ₹1.45 Cr ₹64.13 Lakh ₹55.84 Lakh ₹1.13 Cr ₹2.25 Cr ₹4.29 Cr ₹45.65 Lakh ₹43.97 Lakh
Total Tax Expense ₹41.12 Lakh ₹34.56 Lakh ₹13.9 Lakh ₹23.34 Lakh ₹65.37 Lakh ₹1.01 Cr ₹12.82 Lakh ₹3.28 Lakh
Net Profit ₹1.04 Cr ₹29.57 Lakh ₹41.94 Lakh ₹89.22 Lakh ₹1.59 Cr ₹3.28 Cr ₹32.83 Lakh ₹40.69 Lakh
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income ₹1.04 Cr ₹29.57 Lakh ₹41.94 Lakh ₹89.22 Lakh ₹1.59 Cr ₹3.28 Cr ₹32.83 Lakh ₹40.69 Lakh
EBITDA (computed) ₹4.26 Cr ₹3.78 Cr ₹3.69 Cr ₹4.35 Cr ₹5.69 Cr ₹3.31 Cr ₹3.46 Cr ₹3.74 Cr
Basic EPS ₹0.93 ₹0.30 ₹0.42 ₹0.96 ₹1.82 ₹3.75 ₹0.38 ₹0.52
Diluted EPS ₹0.93 ₹0.30 ₹0.42 ₹0.96 ₹1.82 ₹3.75 ₹0.38 ₹0.52
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹71.85 Cr ₹58.58 Cr ₹56.3 Cr ₹56.63 Cr ₹56.45 Cr ₹49.88 Cr ₹58.02 Cr ₹82.77 Cr
Non-current Assets ₹22.38 Cr ₹25.16 Cr ₹14.92 Cr ₹15.23 Cr ₹14.55 Cr ₹13.87 Cr ₹12.45 Cr ₹13.03 Cr
Current Assets ₹49.47 Cr ₹33.42 Cr ₹41.38 Cr ₹41.4 Cr ₹41.89 Cr ₹36.01 Cr ₹45.56 Cr ₹69.74 Cr
Property, Plant & Equipment ₹10.91 Cr ₹11.54 Cr ₹10.99 Cr ₹12.22 Cr ₹13.33 Cr ₹13.19 Cr ₹9.74 Cr ₹11.06 Cr
Inventories ₹18.35 Cr ₹19.13 Cr ₹18.5 Cr ₹17.5 Cr ₹17.49 Cr ₹11.87 Cr ₹16.43 Cr ₹18.64 Cr
Trade Receivables ₹28.13 Cr ₹12.67 Cr ₹21.07 Cr ₹16.35 Cr ₹22.86 Cr ₹20.73 Cr ₹25.45 Cr ₹48.43 Cr
Cash & Equivalents ₹27.1 Lakh ₹11.54 Lakh ₹13.71 Lakh ₹7.53 Lakh ₹4.44 Lakh ₹3.55 Lakh ₹1.21 Lakh ₹15.89 Lakh
Equity (Net Worth) ₹48.51 Cr ₹34.11 Cr ₹33.82 Cr ₹31.7 Cr ₹28.36 Cr ₹26.77 Cr ₹23.48 Cr ₹23.16 Cr
Equity Share Capital ₹13.18 Cr ₹10 Cr ₹10 Cr ₹9.32 Cr ₹8.74 Cr ₹8.74 Cr ₹8.74 Cr ₹7.86 Cr
Borrowings (Non-current) ₹1.81 Cr ₹1.31 Cr ₹2.67 Lakh ₹1.02 Cr ₹2.48 Cr ₹60.3 Lakh ₹87.72 Lakh ₹68.97 Lakh
Borrowings (Current) ₹9.8 Cr ₹13.55 Cr ₹13.98 Cr ₹13.78 Cr ₹13.95 Cr ₹12.37 Cr ₹8.69 Cr ₹9.14 Cr
Total Debt (computed) ₹11.61 Cr ₹14.86 Cr ₹14.01 Cr ₹14.8 Cr ₹16.43 Cr ₹12.97 Cr ₹9.57 Cr ₹9.83 Cr
Current Liabilities ₹18.02 Cr ₹19.62 Cr ₹19.44 Cr ₹20.9 Cr ₹22.86 Cr ₹19.38 Cr ₹30.98 Cr ₹56.08 Cr
Total Liabilities ₹23.34 Cr ₹24.47 Cr ₹22.48 Cr ₹24.93 Cr ₹28.08 Cr ₹23.12 Cr ₹34.53 Cr ₹59.61 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹7.37 Cr ₹3.16 Cr ₹1.96 Cr ₹2.24 Cr ₹77.42 Lakh
Investing Cash Flow -₹1.13 Cr -₹2.32 Cr -₹1.21 Cr -₹2.27 Cr -₹2.44 Cr
Financing Cash Flow ₹8.65 Cr -₹86.65 Lakh -₹68.94 Lakh ₹5.16 Lakh ₹1.68 Cr
Capital Expenditure ₹1.17 Cr ₹2.33 Cr ₹1.02 Cr ₹85.66 Lakh ₹2.46 Cr
Free Cash Flow (computed) -₹8.53 Cr ₹83.05 Lakh ₹94.19 Lakh ₹1.39 Cr -₹1.68 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash ₹15.56 Lakh -₹2.16 Lakh ₹6.19 Lakh ₹3.08 Lakh ₹89,400
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹35.55 Cr ₹16.84 Cr ₹23.46 Cr ₹13.38 Cr ₹79.4 Lakh ₹10.77 Cr ₹11.84 Cr ₹6.35 Cr
Other Income ₹1.08 Lakh ₹2.12 Lakh ₹24,000 ₹0 ₹48,000 ₹0 ₹95,700 ₹100
Total Income ₹35.56 Cr ₹16.86 Cr ₹23.46 Cr ₹13.38 Cr ₹79.88 Lakh ₹10.77 Cr ₹11.85 Cr ₹6.35 Cr
Cost of Materials Consumed ₹31.81 Cr ₹14.33 Cr ₹18.49 Cr ₹10.69 Cr ₹6.04 Cr ₹8.51 Cr ₹9.79 Cr ₹3.88 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹7.08 Lakh ₹77,000 ₹56.13 Lakh ₹60.64 Lakh -₹74.49 Lakh -₹22.76 Lakh ₹4.03 Lakh ₹35.16 Lakh
Employee Benefit Expense ₹1.73 Cr ₹1.22 Cr ₹1.95 Cr ₹87.11 Lakh ₹1.53 Cr ₹94.51 Lakh ₹86.12 Lakh ₹1.05 Cr
Finance Costs ₹34.46 Lakh ₹29.6 Lakh ₹81.85 Lakh ₹41.99 Lakh ₹53.48 Lakh ₹42.58 Lakh ₹38.75 Lakh ₹37.03 Lakh
Depreciation & Amortisation ₹35.05 Lakh ₹30.44 Lakh ₹70.24 Lakh ₹36.55 Lakh ₹37.45 Lakh ₹36.72 Lakh ₹34.09 Lakh ₹33.54 Lakh
Other Expenses ₹52.85 Lakh ₹40.61 Lakh ₹64.61 Lakh ₹27.94 Lakh ₹20.64 Lakh ₹23.21 Lakh ₹35.65 Lakh ₹33.83 Lakh
Total Expenses ₹34.83 Cr ₹16.57 Cr ₹23.17 Cr ₹13.23 Cr ₹7.95 Cr ₹10.25 Cr ₹11.78 Cr ₹6.33 Cr
Profit Before Exceptional Items & Tax ₹73.46 Lakh ₹29.28 Lakh ₹28.62 Lakh ₹15.2 Lakh -₹7.15 Cr ₹52.07 Lakh ₹7.37 Lakh ₹2.64 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹73.46 Lakh ₹29.28 Lakh ₹28.62 Lakh ₹15.2 Lakh -₹7.15 Cr ₹52.07 Lakh ₹7.37 Lakh ₹2.64 Lakh
Total Tax Expense ₹21.79 Lakh ₹7.76 Lakh ₹8.07 Lakh ₹4.06 Lakh ₹1.26 Lakh ₹29.87 Lakh ₹1.96 Lakh ₹1.47 Lakh
Net Profit ₹51.67 Lakh ₹21.52 Lakh ₹20.55 Lakh ₹11.14 Lakh -₹7.16 Cr ₹22.19 Lakh ₹5.42 Lakh ₹1.17 Lakh
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income ₹51.67 Lakh ₹21.52 Lakh ₹20.55 Lakh ₹11.14 Lakh -₹7.16 Cr ₹22.19 Lakh ₹5.42 Lakh ₹1.17 Lakh
EBITDA (computed) ₹1.43 Cr ₹89.32 Lakh ₹1.81 Cr ₹93.74 Lakh -₹6.24 Cr ₹1.31 Cr ₹80.21 Lakh ₹73.21 Lakh
Basic EPS ₹0.46 ₹0.16 ₹0.21 ₹0.11 ₹0.08 ₹0.22 ₹0.05 ₹0.01
Diluted EPS ₹0.46 ₹0.16 ₹0.21 ₹0.11 ₹0.08 ₹0.22 ₹0.05 ₹0.01
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Concord Drugs Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Charges & Borrowings of Concord Drugs Limited

Open charges
₹19.33 Cr
Satisfied charges
₹7.4 Cr
Breakdown by lending institutions
State Bank of India₹18.93 Cr
Others₹0.40 Cr
Latest charge details
DateLenderAmountStatus
25 Feb 2026 Others ₹40 Lakh Open
17 Dec 2011 State Bank of India ₹18.93 Cr Open
11 Mar 2022 Others ₹5 Cr Satisfied
10 Nov 2005 Punjab National Bank ₹1.4 Cr Satisfied
01 Jan 1998 Small Industries Development Bank of India ₹50 Lakh Satisfied

Total charge records: 6 View all charges

Employees and EPFO Compliance at Concord Drugs Limited

View historical data on people associated with Concord Drugs Limited, including employment history and EPFO contributions.

Premium access

Employee and EPFO history for Concord Drugs Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Concord Drugs Limited

Premium access

GST registrations and filing compliance for Concord Drugs Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Concord Drugs Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Concord Drugs Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Concord Drugs Limited

Premium access

MSME payment history for Concord Drugs Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Concord Drugs Limited

Premium access

Corporate group structure for Concord Drugs Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Concord Drugs Limited

Premium access

MCA filings and documents for Concord Drugs Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Concord Drugs Limited

Charges
01 Jul 2026
A charge with State Bank Of India of Rs. 18.93 Cr registered on 17 Dec 2011 with Charge ID 10394597 was modified on 01 Jul 2026.
Charges
25 Feb 2026
A charge with Others amounted to Rs. 0.40 Cr with Charge ID 101249024 was registered on 25 Feb 2026.
Activity
30 Sep 2025
Concord Drugs Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Directors
30 Sep 2025
Satyam Reddy Gopidi was appointed as a Director on 30 Sep 2025 & has been associated with this company since 10 months 25 days.
Activity
31 Mar 2025
Concord Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Directors
08 Apr 2024
Namratha was appointed as a Company Secretary on 08 Apr 2024 & has been associated with this company since 2 years 4 months.

Frequently Asked Questions about Concord Drugs Limited

Concord Drugs Limited is an active public limited company in the pharma sector based in Na, Telangana, India. It was incorporated on 24 April 1995 (31+ years old) and is registered under CIN L24230TG1995PLC020093. Listed on BSE: 538965. The company has 20 employees.

Concord Drugs Limited reported revenue of ₹78.74 Cr for FY 2026 (up 74.02% YoY) based on consolidated BSE filings.

The current directors of Concord Drugs Limited are:

The primary industry of Concord Drugs Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Concord Drugs Limited is listed on BSE with code 538965.

Concord Drugs Limited can be reached at the registered office: Survey No.249 Brahmanapally Village Hayatnagar Mandal R.R.D Ist – 501511, Telangana, India, or through the website concorddrugs.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available